Skip to main content
. 2021 Apr 4;22(7):3752. doi: 10.3390/ijms22073752

Table A6.

EGFR mutation in sensitive or resistant NSCLC cell lines in response to treatment with gefitinib and erlotinib, respectively.

Sensitive Resistant
Gefitinib IC50 HCC4006, HCC827, LOUNH91, NCIH1355, NCIH1568 HCC1359, NCIH1793, NCIH226, SKMES1
EC50 HCC4006, HCC827, NCIH1355, NCIH1568, NCIH1975, NCIH226, PC14 HCC1359, SKMES1
Erlotinib IC50 HCC4006, HCC827, NCIH1355, NCIH1650, NCIH1793
EC50 HCC1359, HCC4006, HCC827, NCIH1355, NCIH1650, NCIH1975, PC14 NCIH226, SKMES1